Atopic Dermatitis

Children born by caesarean section had an increased risk for developing atopic dermatitis before age 5 years compared with children born by vaginal delivery, according to a study published in Pediatric Allergy and Immunology.

Th9 can drive allergic disease and may be targeted in precision medicine treating patients with high levels of this helper T cell, according to a study published in Nature Immunology.

Alphyn Biologics reported positive results for topical AB-101a in a phase 2a clinical trial in pediatric patients with mild to moderate atopic dermatitis.

Tralokinumab at doses of 150 mg or 300 mg was associated with improvements over placebo in a number of efficacy outcomes at 16 weeks and 52 weeks in adolescents with moderate to severe atopic dermatitis, according to a study.

People with allergic diseases had an increased risk for cataract surgery, an association more evident in men aged younger than 50 years and in those with both atopic dermatitis and allergic rhinitis, according to data in Scientific Reports.

Evelo Biosciences has announced that it will cease further development of EDP1815 for atopic dermatitis following its phase 2 study results that showed the primary endpoint was not met, according to a company press release.

A 4 mg dose of baricitinib was associated with significant improvement over placebo in a number of efficacy parameters in patients with moderate to severe atopic dermatitis, according to a study.

Atopic dermatitis is associated with atopic and nonatopic comorbidities as well as ocular, psychiatric, infectious, endocrine, autoimmune and cardiovascular diseases, in addition to some cancers, according to a review.

Compared with adults, upadacitinib exhibited similar efficacy and safety results in adolescents aged 12 to 17 years in the treatment of moderate to severe atopic dermatitis, according to a study.